Abstract 957P
Background
So far there is no neoadjuvant therapy recommended by major hepatocellular carcinoma (HCC) guidelines. In other malignancies, ICIs in the neoadjuvant setting have shown better outcomes than in the adjuvant setting, and the combination of radiation therapy to ICIs incrementally improves the systemic response to ICIs. Neoadjuvant therapy of ICIs plus stereotactic body radiotherapy (SBRT) has shown promising results in several types of solid tumours but not HCC.
Methods
This is a phase Ib clinical trial of neoadjuvant SBRT plus PD-1 (tislelizumab) in HCC patients (pts). Prior to resection, pts receive 8 Gy × 3 SBRT with 2 cycles of PD-1. HCC resection is scheduled 4 weeks after the second PD-1, followed by adjuvant PD-1 for up to 1 year. We plan to enrol 20 participants in this trial. The primary study endpoints include the surgery delay over 6 weeks or later, ORR on pre-resection imaging, pathologic response (pCR) rate, safety and tolerability of the sequential SBRT/PD-1. The secondary endpoints are DFS and OS rates every 3 or 6 months after the hepatic resection.
Results
By 10th May 2023, 11 pts were enrolled, all were BCLC A stage. One pt was excluded due to the protocol violation, in other 10 pts, one just starts the adjuvant therapy, two have completed the neoadjuvant therapy and waiting for the scheduled resection, all other 7 pts have completed the resection, and no surgery delay accrued; DCR reached 100% (RECIST: 1 PR, 6 SD; mRECIST: 1 CR, 2 PR, 3 SD, 1 CR+SD ); pCR was confirmed in two tumors; So far the safety of neoadjuvant SBRT+PD-1 was satisfied, grade 1 to 2 TRAEs, mainly anemia and white blood cell decreasing were common; grade 3 TRAE occurred in 3 pts (1 granulocytopenia and 2 elevated transaminase), but all well-tolerated. One pt developed recurrence 9 months after surgery (RF ablation), all other 6 pts are still in DFS. Table: 957P
Pt # | age (Y) | gender | tumor size (cm) | BCLC stage | RECIST | mRECIST | interval between 2nd PD-1 and surgery | pCR (Y/N) | TARE over grade 3(Y/N) | survival |
1 | 70 | F | S7:2.4×2.2 | A | SD | SD | 31 | N | N | Recurrence/RFA |
2 | 74 | M | S4a:1.6; S2:1.2 | A | SD | S4a:CR; S2:SD | 28 | S4a: Y; S2:N | No | DFS |
3 | 64 | M | S8:1.8×1.6 | A | SD | SD | 28 | N | Y | DFS |
4 | 51 | M | S7/8:6.0×6.1 | A | PR | PR | 26 | Y | Y | DFS |
5 | 70 | M | S4/5:3.7×4.1 | A | SD | PR | 40 | N | N | DFS |
6 | 52 | M | S6/7:4.1×4.0 | A | SD | CR | 28 | N | Y | DFS |
7 | 70 | F | S6:3.3 | A | SD | SD | 34 | N | N | DFS |
8 | 48 | F | S8:2.2×1.7 | A | PR | CR | N | |||
9 | 56 | M | S6:2.9×2.4 | A | N | |||||
10 | 54 | M | S6:4.8×3.3; S8:2.2×1.8 | A | N |
Conclusions
The safety and clinical significance of radiotherapy plus PD-1 as the neoadjuvant therapy in HCC needs further exploration.
Clinical trial identification
NCT05185531.
Editorial acknowledgement
N/A
Legal entity responsible for the study
The authors.
Funding
The Key Research and Development Program of Shandong (Major Science & Technology Innovation Project), 2021SFGC0501. The reported trial is partly funded by BeiGene.
Disclosure
L. Zhao: Financial Interests, Personal, Speaker’s Bureau: Innovent, Hengrui Medicine, MSD, Roche, Bayer; Financial Interests, Personal and Institutional, Speaker’s Bureau. All other authors have declared no conflicts of interest.
Resources from the same session
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18